Maggie is an editor for The American Journal of Managed Care® (AJMC®) and produces written, video, and podcast content covering several disease states. She joined AJMC® in 2019, and has been with AJMC®’s parent company, MJH Life Sciences®, since 2014, when she started as a copy editor.
She has a BA in English from Penn State University. You can connect with Maggie on LinkedIn.
FOENIX Update: A New Era in Cholangiocarcinoma Precision Medicine
July 1st 2022Patients with iCCA, particularly those whose disease progresses following first-line chemotherapy, have limited overall treatment options. Data presented at the 2022 American Society of Clinical Oncology (ASCO) Annual Meeting show that patients may soon have a new agent to fight this rare cancer in futibatinib (Taiho Oncology), an FGFR inhibitor.
Read More
Becerra Unveils HHS’ 5-Step Plan in Response to Roe v Wade Decision
June 28th 2022In response to the Supreme Court last week overturning the landmark 1973 Roe v Wade decision, after previously upholding the constitutional right to an abortion in Planned Parenthood of Southeastern Pennsylvania v Casey, HHS Secretary Xavier Becerra outlined the next steps for the Biden administration.
Read More
Risk for CVD Increases Following INSTI Use for HIV
June 28th 2022A possible connection between integrase strand-transfer inhibitor (INSTI) use for HIV and cardiovascular disease (CVD) was investigated in this new study from an international team wanting more knowledge on the drug class’s treatment effects.
Read More
Gout Flare Likely Increases Hospital LOS in Heart Failure
June 25th 2022Using the Nationwide Inpatient Database for trends studied between 1993 and 2011, investigators from Columbia University Irving Medical Center evaluated hospitalization outcomes among patients with heart failure and comorbid gout.
Read More
Meningococcal Vaccine Uptake Lagging Among People Living With HIV
June 23rd 2022The findings of this study, which used insurance claims data for patients 2 years and older to determine rates of meningococcal A, C, W, Y vaccine uptake, points to the need for more education, the authors said.
Read More
Patients With HFrEF May Benefit From Alternate Method of Sac/Val Dose Titration
June 22nd 2022In this study, Italian investigators evaluated how sacubitril/valsartan (Sac/Val) dose titration among older patients with heart failure with reduced ejection fraction (HFrEF) might affect reverse cardiac remodeling and if the success of up-titration can be predicted.
Read More
There Is More to Blame Than Tech for T1D Outcomes Disparities, Investigators Argue
June 21st 2022Investigators from the Pediatric Diabetes Center at Hassenfeld Children’s Hospital at NYU Langone investigated outcomes disparities as they related to diabetes technology use among youth living with type 1 diabetes (T1D).
Read More
Dr Debra Patt: Telemedicine’s Contribution to Cancer Care Robust and Meaningful
June 20th 2022Debra Patt, MD, PhD, MBA, executive vice president of Texas Oncology, discusses how enhancements to telemedicine precipitated by the COVID-19 pandemic have made lasting and meaningful changes to oncology care, including that these care improvements will persist post pandemic.
Read More
Sacubitril/Valsartan Safe, Effective Among CHF Patients on Maintenance Hemodialysis
June 18th 2022Outcomes in this new study, conducted among patients with chronic heart failure (CHF) on maintenance dialysis and receiving sacubitril/valsartan, were evaluated as they pertained to heart function and blood pressure.
Read More
Caregiver Contributions in Heart Failure Require Further Study
June 16th 2022The primary outcomes of this secondary analysis of the MOTIVATE-HF study were improvement in caregiver self-efficacy while caring for patients living with heart failure and caregiver contributions to self-care for these patients following motivational interviewing.
Read More
Dr Hope S. Rugo Discusses Clinical Trial Minority Recruitment, PALOMA-2 Findings
June 16th 2022Hope S. Rugo, MD, FASCO, is professor of medicine and the director of the Breast Oncology and Clinical Trials Education program at the University of California San Francisco Helen Diller Family Comprehensive Cancer Center. She discusses her experience with palbociclib and letrozole in advanced breast cancer.
Read More
Dr Roxana Siles: QOL Improves Greatly From Effective Chronic Cough Treatment
June 14th 2022Roxana Siles, MD, FAAAAI, staff in the Department of Allergy and Immunology at Cleveland Clinic and codirector of the Asthma Center at Cleveland Clinic, address the impact of effective treatments of chronic cough on patient quality of life (QOL).
Read More
CREATE Trial Data Add to Support of Open-Source AID Use in T1D
June 9th 2022Findings presented at the 82nd Scientific Sessions of the American Diabetes Association support the safety and efficacy of open-source automated insulin delivery (AID) systems among children and adults living with type 1 diabetes (T1D).
Read More
Dr Kim A. Reiss: There Are Several Exciting Developments in Pancreatic Cancer Research
June 6th 2022Kim A. Reiss, MD, assistant program director of the Hematology/Oncology Fellowship Program and assistant professor of medicine at the Hospital of the University of Pennsylvania, discusses pancreatic cancer research she presented at the 2022 American Society of Clinical Oncology Annual Meeting.
Read More
Dr Joel W. Neal: Cabozantinib/Atezolizumab May Fullfill Unmet Targeted Treatment Need in NSCLC
June 6th 2022Joel W. Neal, MD, PhD, associate professor, Division of Oncology, Stanford Cancer Institute, is lead investigator on the COSMIC-021 trial, which is investigating cabozantinib plus atezolizumab vs cabozantinib alone in patients with advanced non–small cell lung cancer (NSCLC) as a possible second-line treatment beyond chemotherapy.
Read More
Dr David R. Penberthy: Knowledge Gained at ASCO Can Transform Cancer Care
June 5th 2022David R. Penberthy, MD, MBA, is medical director, Radiation Oncology, Bon Secours-Southside Medical Center in Petersburg, Virginia, and president of the Association of Community Cancer Centers for the 2022-2023 term.
Read More
Dr Kashyap Patel Discusses the Importance of WES in Reducing Targeted Treatment Disparities
June 4th 2022Kashyap Patel, MD, CEO of Carolina Blood and Cancer Care Associates, current president of the Community Oncology Alliance, and associate editor of Evidence-Based Oncology™, discusses his partnership with Sema4 and LabCorp and their joint goal to advance whole-exome sequencing (WES) for targeted oncology treatment.
Read More
Dr Enrique Ocio Discusses the Advantages of Sub-Q Isatuximab for RRMM
June 4th 2022Enrique Ocio, MD, PhD, hematology department head, Marqués de Valdecilla University Hospital, Santander, Spain, discusses phase 1b trial results for subcutaneous (sub-Q) vs intravenous isatuximab, both formulations administered in combination with pomalidomide and dexamethasone for relapsed/refractory multiple myeloma (RRMM).
Read More
Dr Randall A. Oyer: Clinical Trials Must Be Accessible to Everyone
June 1st 2022Randall A. Oyer, MD, medical director, oncology, and medical director, Cancer Risk Evaluation Program, Lancaster General Health, and clinical professor of cancer biology at Penn Medicine, discusses the recent American Society of Clinical Oncology/Association of Community Cancer Centers recommendations for improving diversity in clinical trials.
Read More
Dr Kashyap Patel Updates on Exciting Developments at ASCO22
June 1st 2022Kashyap Patel, MD, CEO of Carolina Blood and Cancer Care Associates, current president of the Community Oncology Alliance, and associate editor of Evidence-Based Oncology™, talks with us ahead of the 2022 American Society of Clinical Oncology (ASCO) Annual Meeting.
Read More